Clinicians Embracing New Depression Drug Esketamine with ‘Enthusiastic Caution’

March 6, 2019

(STAT News) – Patients with major depression who haven’t responded to other treatments will soon have a new option: esketamine, a rapid-acting therapy derived from the long-used anesthetic ketamine. But the drug’s approval on Tuesday sparked a string of new questions, from how much patients will have to shell out for the drug to how clinicians will be able to accommodate patients who need to be monitored for two hours after every dose.

Recommended Reading